Abstract. Tumor-selective replicating viruses are attractive tools for cancer gene therapy, but generally achieve only transitory tumor suppression. However, replicating retrovirus vectors (RRVs) can achieve highly efficient and tumorselective transduction, as well as persistent expression of transgenes. We therefore developed RRVs that express the yeast cytosine deaminase (yCD) and herpes simplex virus thymidine kinase (TK), which exhibit remarkably enhanced cytotoxicity after administration of the prodrugs 5-fluorocytosine (5-FC) and ganciclovir (GCV) concomitant with the efficiency of their replicative spread, and tested their therapeutic effect in vitro and in vivo. In subcutaneous MDA-MB-435 human breast cancer xenograft models, RRVmediated yCD and TK suicide gene therapy significantly suppressed tumor growth after prodrug administration. Notably, no systemic spread of the vector to extratumoral tissues was detected. Our results thus demonstrate that efficient, tumor-selective, and stable integration achieved by RRVs causes efficient cell killing upon prodrug administration, resulting in significant suppression of tumor growth.
Introduction
Vectors derived from retroviruses have been widely applied for gene transfer to target cells in vitro and in vivo, and in fact retroviruses are used in the majority of gene therapy trials to date (1) . Retrovirus vectors, based on murine leukemia virus (MLV), possess several distinct inherent advantages in cancer gene therapy: achieving transduction only in actively dividing cells (2) (3) (4) ; stable expression of desired transgenes by integration of viral genome into chromosomes of target cells to offer the potential for long-term cure; and low immunogenicity compared to some other virus vectors (5) (6) (7) (8) . Conventional retrovirus vectors are replication-defective retrovirus (RDR) vectors in which the viral genes gag, pol, and env are removed to develop a safer gene delivery carrier. Despite the fact that RDR vectors have been applied for a number of cancer gene therapy clinical trials, the low efficiency of gene transfer in solid tumors exhibited by RDR vectors becomes their major limitation for cancer gene therapy (9) (10) (11) .
In order to improve transduction efficiency of retrovirus vectors, we have developed replicating retrovirus vectors (RRVs) derived from MLV (12) (13) (14) . The RRVs retain a fully native viral genome and thus possess the ability to replicate. In addition to an intact MLV genome including long terminal repeat (LTR), packaging signal (Ψ), and genes gag, pol and env, the RRVs contain an internal ribosome entry site (IRES)-transgene cassette between the env gene and the 3' untranslated region (3' UTR). While the RRVs infect a target tumor cell, each transduced cell itself becomes a virus-producing cell to sustain further transduction events, thus greatly increasing transduction efficiency in vivo.
To evaluate its potential as a therapeutic vector for the treatment of cancer, we incorporated into RRVs the yeast cytosine deaminase (yCD) and herpes simplex virus thymidine kinase (TK) suicide genes. The yCD deaminates the nontoxic prodrug 5-fluorocytosine (5-FC) to the highly toxic metabolite 5-fluorouracil (5-FU) (15) , which is also one of the most active antineoplastic agents in conventional cancer chemotherapy. The TK efficiently monophosphorylates ganciclovir (GCV), a guanosine analog, which is subsequently converted into GCVtriphosphate by endogenous mammalian kinases (16, 17) . Cellular DNA polymerase further incorporates the GCVtriphosphate into replicating DNA, thereby arresting DNA replication and causing cell death (18) .
In this study, we explored the use of RRVs for suicide gene therapy of breast tumors. We examined the survival of transduced tumor cells in vitro as well as tumor growth in vivo after inoculation of RRV followed by treatment with their respective prodrugs. We evaluated whether the significantly higher transduction levels achieved by RRV have the potential to greatly enhance the efficacy of suicide gene therapy for the treatment of breast tumors. (13) is a replication-competent amphotropic MLV vector containing an IRES-GFP sequence positioned between amphotropic env and 3' UTR. The TK gene was amplified from the plasmid pFRA-TK (19) by PCR using Pfu polymerase (Stratagene, La Jolla, CA, USA), and used to replace the GFP sequence in pACE-GFP, generating plasmid pACE-TK. Plasmid pGS4-GFP (20) is a replication-competent gibbon ape leukemia virus (GALV) vector containing an IRES-GFP positioned between the env gene and 3' UTR. The yCD gene sequence was amplified from yeast genome by PCR and was used to replace the GFP sequence in pGS4-GFP, generating plasmid pGS4-yCD.
Materials and methods

Construction of retrovirus vectors. Plasmid pACE-GFP
Cell lines and virus vector production. 293T, MDA-MB-435, and MCF7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA). T47D cells were cultured in DMEM with 10% FBS, 1.5 g/l sodium bicarbonate, 1 mM sodium pyruvate, and 10 μg/ml bovine insulin (Sigma, St. Louis, MO, USA). Virus particles were produced by transient transfection of the RRV-encoding plasmids into 293T cells using calcium phosphate precipitation as described previously (21) . The virus-containing supernatant was collected 2 days post-transfection, filtered through a 0.45-μm filter, and frozen at -80˚C for later use. For titer determination, viral supernatant was added to ~20% confluent tumor cells in the presence of 4 μg/ml polybrene (Sigma) in six-well plates. Viral supernatant was then removed 24 h post-infection, and cells were incubated in regular media with 25 μM AZT (Sigma) for 48 h and were analyzed for GFP and dsRed expression using a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). Retrovirus titer was represented as transducing units per milliliter (TU/ml).
Transduction of tumor cells. MDA-MB-435, MCF7, and T47D cells seeded on six-well plates were infected with virus ACE-GFP at a multiplicity of infection (MOI) of 0.05 in the presence of 4 μg/ml polybrene. At various time points post-infection, the cells were analyzed for GFP expression using flow cytometry. In a separate experiment, MDA-MB-435 cells infected with ACE-GFP or GS4-GFP were mixed with uninfected cells at a ratio of 5% of the cell population and seeded onto six-well plates. At various times after mixing, the total cell population was analyzed for GFP expression by flow cytometry in order to estimate the spread of vectors.
In vitro cytotoxicity of yCD/5-FC and TK/GCV. Uninfected and GS4-yCD-infected MDA-MB-435 cells were mixed at various initial ratios as indicated ( Fig. 3A) and seeded onto replicate 96-well plates (2x10 3 cells per well). After overnight culture, the mixed cell populations were exposed to 1 mM 5-FC or to control medium without 5-FC, and viable cells were determined daily by MTS assay using the CellTiter Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA). Similarly, uninfected and ACE-TKinfected MDA-MB-435 cells were mixed at various initial ratios as indicated ( Fig. 3B ) and were exposed to 10 μg/ml GCV or to regular medium, and viable cells were determined by MTS assay.
Vector spread in subcutaneous tumor models. For the subcutaneous breast tumor model, BALB/c nude mice (National Laboratory Animal Center, Taiwan) were subcutaneously inoculated with cell suspensions (5x10 6 ) consisting of ACE-GFP-transduced MDA-MB-435 mixing with uninfected MDA-MB-435 at a ratio of 1% of the cell population. Four and six weeks after tumor implantation, tumors were dissected, washed with cold Hank's balanced salt solution, minced into small pieces, and digested with 0.2% collagenase/dispase (Roche Diagnostics Corporation, Indianapolis, IN, USA). The dissociated cells were spun down, resuspended in PBS, and passed through a 100-μm cell strainer (Becton Dickinson). The cells were immediately subjected to flow cytometry for GFP expression analysis. In a second experiment, nude mice were subcutaneously inoculated with cell suspensions (5x10 6 ) consisting of ACE-GFP transduced or GS4-GFP transduced MDA-MB-435 mixing with uninfected MDA-MB-435 at a ratio of 5% of the cell population. Four weeks after tumor implantation, tumor cells were harvested as previously described and were subjected to flow cytometric analysis. In vivo therapeutic efficacy of yCD/5-FC and TK/GCV. Ten BALB/c nude mice were inoculated with 5x10 6 MDA-MB-435 cells pretransduced with GS4-yCD into the right dorsal flank. Seventeen days after tumor cell implantation, five mice received intraperitoneal injections of 5-FC (500 mg/kg), while the remaining five mice received PBS injections, once daily, for a total of 10 treatments. In a second experiment, nude mice were subcutaneously inoculated with cell suspensions (5x10 6 ) consisting of GS4-yCD-transduced and ACE-TKtransduced MDA-MB-435 mixing with uninfected MDA-MB-435 at a ratio of 5% of the cell population (2.5% GS4-yCD-transduced; 2.5% ACE-TK-transduced). When the tumors were ~400 mm 3 in size, mice in the uninfected group and in the group of 2.5% yCD + 2.5% TK received daily injections of 5-FC (500 mg/kg) for 7 days, followed by daily injections of GCV (30 mg/kg) for 7 days.
Real-time PCR. To detect any integrated RRV sequences in genomes, real-time PCR was performed (using the ABI Prism 7700 sequence detector), targeting the 4070A amphotropic (22) and GALV envelope genes. The primers were designed to target the 4070A envelope (forward: 5'-ACCCT CAACCTCCCCTACAAG-3'; reverse: 5'-GTTAAGCGCC TGATAGGCTC-3') and GALV envelope (forward: 5'-CCT ATTACTCCTCCTTCTGTTG-3'; reverse: 5'-GGGCCTGA TATTTTTGTCTAAG-3'). Apolipoprotein B gene for precise amounts of input genomic DNA were also quantified as an internal control (forward: 5'-CACGTGGGCTCCAGCATT-3'; reverse: 5'-TCACCAGTCATTTCTGCCTTTG-3'). Real-time PCR was done in 25 μl of reaction mixture containing genomic DNA, 12.5 μl of 2X SYBR green real-time PCR master mix (Toyobo, Osaka, Japan) and 300 nM of each primer. Each sample was analyzed in triplicate, using 15 ng of genomic DNA in each reaction. Products were amplified by 45 cycles of successive incubation at 95˚C for 15 sec and at 60˚C for 1 min. A standard curve for RRV copy number was generated by amplification of serially diluted RRV plasmid at specific copy numbers mixed into genomic DNA from spleen cells of uninfected mice.
Results
High efficiency transduction of breast tumor cells by RRVs.
We have previously described the construction of ACE-GFP vector, an RRV based on amphotropic MLV containing an IRES-GFP expression cassette (Fig. 1) (13) . To test the efficacy of ACE-GFP to transduce human breast tumor cells in culture, we infected MDA-MB-435, T47D, MCF7 with ACE-GFP at an MOI of 0.05 and checked viral transduction by flow cytometry. Our results showed that ACE-GFP can efficiently transduce each breast tumor cell line and spread throughout entire cell populations ( Fig. 2A) . We further evaluated the replication kinetics of ACE-GFP and GS4-GFP by preparing a cell mixture in which MDA-MB-435 infected with ACE-GFP or GS4-GFP were mixed with uninfected MDA-MB-435 at a ratio of 5% of the cell population and were seeded onto six-well plates. Flow cytometric analysis showed that both vectors could efficiently transfer the GFP gene to MDA-MB-435 and spread throughout entire cell populations (Fig. 2B) . To study whether GS4 and ACE vectors could co-infect MDA-MB-435, we infected GS4-dsRedtransduced MDA-MB-435 with ACE-GFP at an MOI of 0.05 and checked viral transduction by flow cytometry. Images of flow cytometric analysis show that GS4-dsRed-transduced MDA-MB-435 infected with ACE-GFP eventually expressed both of dsRed and GFP, indicating that the cells could be co-infected with GS and ACE vectors (Fig. 2C) .
Cytotoxic efficacy of RRV-mediated suicide gene therapy in vitro.
GS4-yCD-transduced MDA-MB-435, mixed with uninfected MDA-MB-435 at varying percentages, were or were not treated with 5-FC, and viability of the cells was normalized to that of a negative control composed of uninfected MDA-MB-435 without 5-FC. When even as few as 1% of the MDA-MB-435 cells in culture initially expressed yCD, substantial cell death was observed over time after incubation with 5-FC (Fig. 3A) . The kinetics and efficiency of cell killing was highly dependent on the initial fraction of cells in the culture expressing yCD, as higher percentages of transduced cells in the culture achieved correspondingly faster clearance of the tumor cell population and correlated with the kinetics of viral replication. To examine the cytotoxic efficacy of ACE-TK, we treated ACE-TK-transduced MDA-MB-435 mixed with uninfected cells at varying percentages with prodrug GCV. Similarly, we observed that ACE-TK/GCV caused substantial cell death when 10% and 100% of the MDA-MB-435 tumor cells initially expressed TK (Fig. 3B) . To determine whether co-infection with GS4-yCD and ACE-TK could further enhance tumor cell killing, we treated MDA-MB-435 cells co-transduced by GS4-yCD and ACE-TK with 5-FC, GCV, or both for 5 days. Our result shows that when cells were treated with both prodrugs the highest level of cell killing was observed, indicating that dual-vector gene therapy achieved better cytotoxic efficacy than singlevector gene therapy (Fig. 3C ).
Efficient and progressive spread of RRVs in MDA-MB-435 subcutaneous tumors.
To determine the ability of RRVs to achieve efficient transduction in solid tumors in vivo, we then tested RRV in a subcutaneous MDA-MB-435 tumor model. A cell suspension consisting of ACE-GFP-transduced MDA-MB-435 mixed with uninfected MDA-MB-435 at a ratio of 1% of the cell population was injected into the right dorsal flank of nude mice. The spread of RRVs in tumors was examined by quantification of GFP expression at various time points after tumor implantation. The percentage of GFPpositive cells in tumors was 22.1% at 4 weeks and 42.5% at 6 weeks after tumor implantation (Fig. 4A ). These results demonstrate that ACE-GFP is capable of efficient and progressive transduction of the MDA-MB-435 solid tumor in vivo. To compare the spreading efficiency of ACE and GS4 vectors in vivo, we prepared a cell mixture in which MDA-MB-435 infected with ACE-GFP or GS4-GFP were mixed with uninfected MDA-MB-435 at a ratio of 5% of the cell population and were implanted to right dorsal flank of nude mice. Through flow cytometric analysis of dissected tumors, the percentage of GFP-positive cells was determined to be 53.0±2.3% (ACE-GFP) and 75.6±2.9% (GS4-GFP) at 4 weeks after implantation of tumors (Fig. 4B) .
RRVs suppress the growth of MDA-MB-435 tumors after treatment with prodrugs.
To evaluate any inhibitory effect of yCD/5-FC on tumor progression, mice bearing GS4-yCD pretransduced subcutaneous tumors were treated with PBS or 5-FC. The control group (100% yCD/PBS) showed progressive tumor enlargement, and in contrast, the group treated with GS4-yCD plus 5-FC (100% yCD/5-FC) showed progressive tumor shrinkage (Fig. 5A) . Next, to determine whether a lower ratio of tumor cells expressing RRV could suppress tumor growth, we treated mice bearing subcutaneous MDA-MB-435 tumors in which 5% (2.5% GS4-yCD-transduced; 2.5% ACE-TK-transduced) of the cells initially expressed RRVs with prodrugs 5-FC and GCV. GS4-yCD+ACE-TK/ 5-FC+GCV treatment resulted in significant suppression of tumor growth, compared with the control group (neg/ 5-FC+GCV) (Fig. 5B) .
Biodistribution of RRVs during prolonged replication in animals.
To estimate the biosafety of RRV for gene therapy in vivo, we did a quantitative real-time PCR analysis of genomic DNA extracted from tumors and extratumoral organs using primers specific for the 4070A amphotropic envelope and GALV envelope. Mouse apolipoprotein B gene for precise amounts of input genomic DNA were also quantified as an internal control. As expected, RRV was readily detected in the GS4-yCD and ACE-TK transduced MDA-MB-435 tumors by PCR amplification of both envelope sequences. However, no detectable RRV signals were observed in genomic DNA from extratumoral organs including heart, liver, spleen and bone marrow in the same animals (data not shown).
Discussion
This study demonstrates that RRVs can efficiently transduce and stably propagate in human tumor cells in vitro, and can achieve high transduction efficiency in vivo compared to conventional RDR vectors previously employed in clinical trials (10) . In vitro cytotoxicity studies showed that substantial tumor cell killing can be achieved when initially even as few as 1% of the tumor cells were producing RRVs, indicating that the highly efficient gene transfer by progressive replicative spread from the initial inoculum greatly increased suicide gene toxicity. Flow cytometric analyses and PCR analyses demonstrated that RRV replication in vivo was efficient and was highly restricted to the tumor tissue itself, suggesting that the absolute requirement for cell division results in a high degree of tumor selectivity. While the possibility that the RRV might transduce non-cancerous but actively replicating cells, such as neovascular endothelial cells, requires further careful examination, the incorporation of suicide genes into the RRV ensures that inadvertently transduced non-cancerous cells will have a high probability of eventually being killed, and that the spread of the RRV will be self-limited.
Infections of MDA-MB-435 with ACE-GFP and GS4-GFP at MOI 0.05 demonstrated that ACE and GS4 vectors replicated in these cells at comparable rates and eventually spread throughout entire cell populations. While ACE vector uses the Pit-2 phosphate transporter for viral entry, the GS4 vector uses the Pit-1 phosphate transporter (23) . As expected, ACE-GFP and GS4-dsRed were able to co-infect MDA-MB-435 cells because both of the GFP and dsRed reporter genes are expressed in the cells. Co-infections of MDA-MB-435 in vitro with GS4-yCD and ACE-TK demonstrated that dualvector suicide gene therapy could achieve better cytotoxic efficacy than single-vector suicide gene therapy.
In vivo RRV-mediated dual-vector suicide gene therapy at MOI 0.05 efficiently suppressed MDA-MB-435 tumor growth, showing similar ability to inhibit tumors as achieved in yCD pretransduced tumors after prodrug administration, indicating that the high efficiency of gene transfer by replicative spread of RRV greatly augmented the efficacy of suicide gene therapy. Indeed, a higher MOI might achieve even more efficient tumor inhibition in the MDA-MB-435 tumor model; nonetheless, it should be noted that this level of initial transduction was intended to be comparable to that previously reported by injection of packaging cells producing conventional RDR vectors in clinical trials (10) , and the growth suppression achieved in this study was considerably greater than would be expected from conventional vectors at such a low MOI.
Additional levels of RRV selectivity and safety may also be achieved by vector targeting through replacement of the retroviral promoter with cell-specific transcriptional elements to target viral gene expression to particular tissues (12, 24) . This may also eventually be achieved by modification of cellbinding tropism through direct engineering of the retroviral envelope (25) or by incorporation into adenovirus-retrovirus hybrid vectors (26) with fiber modifications, thus restricting virus entry and/or replication exclusively to tumor cells, and thereby minimizing the potential risk to recipients. In conclusion, in the case of poor prognosis malignancies such as breast cancer, the use of RRVs may represent a promising experimental therapeutic strategy, particularly if the benefits justify the potential risks. With their ability to efficiently and stably transduce tumors in vivo, RRVs may achieve sufficiently persistent expression of transgenes that can achieve significant tumor inhibition and provide long-term survival benefit.
